CompletedPhase 3NCT00025090
Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal Cancer
Studying Carcinoma of the anal canal
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University College London (UCL) Cancer Institute
- Principal Investigator
- Roger D. James, MDMaidstone Hospital
- Intervention
- cisplatin(drug)
- Enrollment
- 600 enrolled
- Eligibility
- All sexes
- Timeline
- 2001 – 2007
Study locations (13)
- Northwick Park Hospital, Harrow, England, United Kingdom
- Ipswich Hospital, Ipswich, England, United Kingdom
- Cookridge Hospital, Leeds, England, United Kingdom
- Saint Bartholomew's Hospital, London, England, United Kingdom
- Cancer Research UK and University College London Cancer Trials Centre, London, England, United Kingdom
- James Cook University Hospital, Middlesbrough, England, United Kingdom
- Mount Vernon Cancer Centre at Mount Vernon Hospital, Northwood, England, United Kingdom
- Nottingham City Hospital, Nottingham, England, United Kingdom
- Royal Marsden - Surrey, Sutton, England, United Kingdom
- Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, England, United Kingdom
- Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom
- Velindre Cancer Center at Velindre Hospital, Cardiff, Wales, United Kingdom
- Cancer Research Centre at Weston Park Hospital, Sheffield, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00025090 on ClinicalTrials.govOther trials for Carcinoma of the anal canal
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07029152Screening for Anal Cancer in Men Who Have Sex With Men Using Pre-Exposure ProphylaxisUniversitair Ziekenhuis Brussel
- ACTIVE NOT RECRUITINGPHASE3NCT06866574A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese MalesXiamen University
- RECRUITINGPHASE2NCT06640283Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical OutcomesInstituto do Cancer do Estado de São Paulo
- RECRUITINGNANCT06792604Host Genome Methylation: a Screening Tool in Anal Cancer DetectionAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE3NCT06207981Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCAFederation Francophone de Cancerologie Digestive
- RECRUITINGPHASE2NCT05661188Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)Grupo Espanol Multidisciplinario del Cancer Digestivo
- RECRUITINGNCT06327568Anal Cancer and/or Precancer Screening: Performance Analysis of the BD Onclarity™ HPV Assay on Anal SpecimensEuropean Institute of Oncology
- RECRUITINGNCT05438836Re-optimization Based Online Adaptive Radiotherapy of Anal CancerHerlev Hospital